NMDA Receptor Glycine Binding Site Modulators for Prevention and Treatment of Ketamine Use Disorder.
Pharmaceuticals (Basel, Switzerland) May 30, 2023 Yu-Chin Hsiao, Mei-Yi Lee, Ming-Huan Chan et al.
Ketamine offers a fast-acting approach to relieving treatment-resistant depression, but its abuse potential is an issue of concern. As ketamine is a noncompetitive N-methyl-D-aspartate receptor (NMDAR) ion channel blocker, modulation of NMDAR might be an effective strategy to counteract the abuse liability of ketamine and even to treat ketamine use disorder. This study evaluated whether NMDAR...